MMV609 University of Kentucky
Product vision |
- Uncomplicated malaria treatment
|
MoA |
- PfATP4; ganaplacide (KAE609) and SJ733
|
Key features |
- Fast-acting against all species
- Predicted 40 mg single-dose
- Transmission-blocking activity
|
Challenges |
- High resistance risk (including G358S mutant)
- Same MoA as Phase II compounds: cipargamin and SJ733
- Synthetic route optimization and cost of goods
- Limited solubility
|
Status |
|
Next milestone |
- Establish funding and collaboration model
- Synthetic route optimization
- Start Good Laboratory Practice (GLP) toxicology program
|
Previously |
- Discovery collaboration with Kip Guy (University of Kentucky)
- MMV609; Full reference MMV1793609
|
MMV Project Director |
|